Moreover, our study revealed decreased rates of AMI, CHF, and arrhythmias in SGLT2 inhibitor users without a CVD history, and while not statistically significant, these findings suggest a protective effect and cardiovascular benefits. This evidence concerns the gene SLC5A2 and Arrhythmia.